Biodexa Pharmaceticals Earnings Estimate

By analyzing Biodexa Pharmaceticals' earnings estimates, investors can diagnose different trends across Biodexa Pharmaceticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Biodexa Pharmaceticals is based on EPS before non-recurring items and includes expenses related to employee stock options. Biodexa Pharmaceticals is projected to generate -0.75 in earnings per share on the 31st of December 2024. Biodexa Pharmaceticals earnings estimates module stress-tests analyst consensus about projected Biodexa Pharmaceticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Biodexa Pharmaceticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Biodexa Pharmaceticals' earnings estimates, investors can diagnose different trends across Biodexa Pharmaceticals' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to drop to about (3.9 M) in 2024. Pretax Profit Margin is likely to drop to -20.63 in 2024Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.